Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.